605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

Polyunsaturated fatty acids control lipid membrane dynamics and ferroptosis sensitivity in B cell lymphoma

USP28 inhibition upregulates CD20 via c myc suppression and synergizes with anti CD20 immunotherapy in B cell lymphomas

BMS 986458 a first in class highly selective and potent ligand directed degrader LDD of B cell lymphoma 6 BCL6 combined with T cell engagers TCEs demonstrates preclinical synergistic antitumor efficacy for the treatment of B cell non Hodgkin lymphoma NHL

Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non Hodgkin lymphoma NHL B cells

Pre treatment ZNF683 effector CD8 T cells predict response to BiTE therapy in acute lymphoblastic leukemia Insights from single cell and TCR sequencing

Serine glycine starvation induces metabolic rewiring to uncover ATF4 driven therapeutic vulnerabilities in infant ALL

Golcadomide demonstrates potent antiproliferative activity in T cell lymphoma via degradation of IKZF1 and IKZF3

Chick embryo xenograft model of multiple myeloma recapitulates immune response systemic dissemination and sensitivity to anti myeloma therapeutics

Molecular subtypes and BH3 mimetic synergy with anti leukemia agents in T cell acute lymphoblastic leukemia

RPT1G a novel hyperbolic NAMPT inhibitor is highly effective against B cell non Hodgkin s lymphoma with germinal center origin

Overcoming leukemia stem cells via targeting AKT wnt ß catenin by AI powered mRNA delivery of peptides

Inhibition of PRMT5 with JNJ 64619178 sensitizes B cell non Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis

NSUN2 YBX1 mediated m5C modification enhances phgdh expression to drive immune evasion via PD L1 and CCL2 axis in high grade b cell lymphoma

Novel EIF4A1 inhibitors with anti-tumor activity